Black patients remain underrepresented in clinical trials, especially in studies of rare diseases, because they are not being recruited, Mary McGowan, CEO of the Foundation for Sarcoidosis Research (FSR), told Scrip.
Trials In Focus: Patient Advocacy Group Takes Trial Diversity To Capitol Hill
The Foundation for Sarcoidosis Research briefed US Congress on participation by Black patients in sarcoidosis and other rare disease trials. Also, the US FDA issued a draft guidance on psychedelic drug trials; Insilico is taking its AI-discovered IPF drug into Phase II; and Compugen and Jasper dosed patients in their oncology trials.
